PRECIGEN, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 637.89K shares, a 1175.79% increase year-over-year.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 134.23K shares, a 7.10% decline year-over-year.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 95.57K shares.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 496.23K shares, a 116.70% increase year-over-year.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 786.28K shares, a 196.21% increase from fiscal 2024.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 265.45K shares.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 637.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 1.36M shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 134.23K shares 10-Q · filed 2026-05-13 | 776.03K shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 95.57K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 786.28K shares 10-K · filed 2026-03-25 |
| 2025-09-30 | 496.23K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 690.71K shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-06-30 | 50.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 423.48K shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-03-31 | 144.49K shares 10-Q · filed 2025-05-14 | 409.94K shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 265.45K shares 10-K · filed 2026-03-25 |
| 2024-09-30 | 228.99K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 265.45K shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-06-30 | 36.46K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 36.46K shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-14 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 0.00 shares 10-K · filed 2026-03-25 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |